Characterisation of the immune response to type I collagen in scleroderma

This study was conducted to examine the frequency, phenotype, and functional profile of T lymphocytes that proliferate in response to type I collagen (CI) in patients with scleroderma (SSc). Peripheral blood mononuclear cells (PBMCs) from SSc patients, healthy controls, and rheumatoid arthritis disease controls were labeled with carboxy-fluorescein diacetate, succinimidyl ester (CFSE), cultured with or without antigen (bovine CI) for 14 days, and analysed by flow cytometry. Surface markers of proliferating cells were identified by multi-color flow cytometry. T-cell lines were derived after sorting for proliferating T cells (CFSElow). Cytokine expression in CI-responsive T cells was detected by intracellular staining/flow cytometry and by multiplex cytokine bead assay (Bio-Plex). A T-cell proliferative response to CI was detected in 8 of 25 (32%) SSc patients, but was infrequent in healthy or disease controls (3.6%; p = 0.009). The proliferating T cells expressed a CD4+, activated (CD25+), memory (CD45RO+) phenotype. Proliferation to CI did not correlate with disease duration or extent of skin involvement. T-cell lines were generated using in vitro CI stimulation to study the functional profile of these cells. Following activation of CI-reactive T cells, we detected intracellular interferon (IFN)-γ but not interleukin (IL)-4 by flow cytometry. Supernatants from the T-cell lines generated in vitro contained IL-2, IFN-γ, GM-CSF (granulocyte macrophage-colony-stimulating factor), and tumour necrosis factor-α, but little or no IL-4 and IL-10, suggesting that CI-responsive T cells express a predominantly Th1 cytokine pattern. In conclusion, circulating memory CD4 T cells that proliferate to CI are present in a subset of patients with SSc, but are infrequent in healthy or disease controls.

[1]  C. Weyand,et al.  CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. , 1996, The Journal of clinical investigation.

[2]  L. Fabbri,et al.  Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. , 1999, Journal of immunology.

[3]  B. Osterud,et al.  Evidence for exclusive role of the p55 tumor necrosis factor (TNF) receptor in mediating the TNF-induced collagenase expression by human dermal fibroblasts. , 1996, The Journal of investigative dermatology.

[4]  F. Arnett,et al.  Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. , 1999, Journal of immunology.

[5]  H. Taskov,et al.  Humoral and cellular immune response to elastin in patients with systemic sclerosis. , 1997, Autoimmunity.

[6]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[7]  B. Corrin,et al.  Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. , 1995, The European respiratory journal.

[8]  S. Pahwa,et al.  Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. , 1994, Annals of allergy.

[9]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[10]  E. Leroy,et al.  Cellular immunity to collagen and laminin in scleroderma. , 1985, Arthritis and rheumatism.

[11]  M. Hasegawa,et al.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. , 2001, Journal of dermatological science.

[12]  B. Berman,et al.  Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation , 1985, The Journal of experimental medicine.

[13]  S. Jimenez,et al.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy. , 1987, Clinical and experimental immunology.

[14]  S. Atamas,et al.  Interleukin 4 in Systemic Sclerosis: Not Just an Increase , 1999, Clinical Diagnostic Laboratory Immunology.

[15]  P. Ward,et al.  Cellular sensitivity to collagen in bleomycin-treated rats. , 1982, Journal of immunology.

[16]  H. McFarland,et al.  CD4+CD28- costimulation-independent T cells in multiple sclerosis. , 2001, The Journal of clinical investigation.

[17]  L. Chess,et al.  Expression of the α1β1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells , 2003 .

[18]  R. Crystal,et al.  Pathogenic mechanisms in pulmonary fibrosis: collagen-induced migration inhibition factor production and cytotoxicity mediated by lymphocytes. , 1976, The Journal of clinical investigation.

[19]  M. Feldmann,et al.  The method of deriving human T‐cell clones alters the proportion of IL‐10‐producing cells , 1996, Immunology.

[20]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[21]  M. Jinnin,et al.  Antagonistic Effects of TNF-α on TGF-β Signaling Through Down-Regulation of TGF-β Receptor Type II in Human Dermal Fibroblasts1 , 2003, The Journal of Immunology.

[22]  A. Vallejo,et al.  Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. , 1999, Journal of immunology.

[23]  C. Platsoucas,et al.  Is systemic sclerosis an antigen-driven T cell disease? , 2004, Arthritis and rheumatism.

[24]  J. R. Reeves,et al.  Cellular infiltrates in scleroderma skin. , 1977, Arthritis and rheumatism.

[25]  Zhaohui Qian,et al.  Ex Vivo Characterization of the Autoimmune T Cell Response in the HLA-DR1 Mouse Model of Collagen-Induced Arthritis Reveals Long-Term Activation of Type II Collagen-Specific Cells and Their Presence in Arthritic Joints1 , 2005, The Journal of Immunology.

[26]  J. Seyer,et al.  Investigation of type I and type III collagens of the lung in progressive systemic sclerosis. , 1981, Arthritis and rheumatism.

[27]  H. Katai,et al.  Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. , 1992, The Journal of clinical investigation.

[28]  B. White,et al.  Immunopathogenesis of systemic sclerosis. , 1996, Rheumatic diseases clinics of North America.

[29]  T. Whiteside,et al.  Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. , 1984, Arthritis and rheumatism.

[30]  J. Seyer,et al.  Collagen polymorphism in normal and cirrhotic human liver. , 1977, The Journal of clinical investigation.

[31]  M. Fujimoto,et al.  Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. , 1997, The Journal of rheumatology.

[32]  S. Maleki,et al.  Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. , 2003, The Journal of clinical investigation.

[33]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.

[34]  G. Delespesse,et al.  Human naive CD4 T cells produce interleukin‐4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions , 1995, European journal of immunology.

[35]  A. Kang,et al.  Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis. , 1976, The Journal of laboratory and clinical medicine.

[36]  R. Wise,et al.  Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. , 1999, Arthritis and rheumatism.

[37]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[38]  C. Mele,et al.  Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis. , 1991, Arthritis and rheumatism.

[39]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[40]  A. Reddi,et al.  Extracellular matrix biochemistry , 1984 .

[41]  S. Todesco,et al.  Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. , 1993, Annals of the rheumatic diseases.

[42]  R. Scorza,et al.  Increased interferon‐gamma (IFN‐γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon , 1999, Clinical and experimental immunology.

[43]  J. Hales,et al.  Potent Costimulation of Effector T Lymphocytes by Human Collagen Type I1 , 2000, The Journal of Immunology.

[44]  L. Carbone,et al.  Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. , 2000, Arthritis and rheumatism.

[45]  T. Medsger,et al.  Soluble serum interleukin 2 receptors in patients with systemic sclerosis. , 1996, The Journal of rheumatology.